Myelopreservation With the CDK4/6i Trilaciclib in Patients With SCLC…

UNC Lineberger Comprehensive Cancer Center

J. Weiss

Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression in E…

Jerome Goldschmidt

Importance of Addressing Myelosuppression in Chemotherapy Patients

Edgardo Santos​

Small Cell Lung Cancer: A Brief Review of the Treatment Landscape

Dana-Farber Cancer Institute

J. Sands

Myelosuppression in ES-SCLC Therapy

Maen Hussein

Nebraska Oncology Society 2022 SCLC Management Updates

Nebraska Oncology Society

T. Leal

Treatment Landscape of SCLC

Edgardo Santos​

Trilaciclib and the Economic Value of Multilineage Myeloprotection F…

Ivo Abraham

ASCO 2022 on KEYVIBE-008: Randomized, Phase 3 Study of 1L Vibostolim…

ASCO 2022 Conference Coverage

J. Sands

ASCO 2022 on Stereotactic Radiosurgery vs. WBRT in SCLC and Intracra…

ASCO 2022 Conference Coverage

K. Gaebe

ASCO 2022 Impact of Trilaciclib on Multilineage Chemo-Induced Myelos…

ASCO 2022 Conference Coverage

J. Goldschmidt

ASCO 2022 on Phase 3 ATLANTIS Trial: Analysis of Patients With Relap…

ASCO 2022 Conference Coverage

A. Navarro

Lecture Summary - ASCO 2022 on Stereotactic Radiosurgery vs. WBRT in…

ASCO 2022 Conference Coverage

K. Gaebe

Lecture Summary - ASCO 2022 Analysis of Patients With Relapsed SCLC …

ASCO 2022 Conference Coverage

A. Navarro